Plot No.367, Abhey Pur, Industrial Area Phase-1, Panchkula, Haryana 134109
Don't miss out on this limited-time offer to join our successful PCD Pharma network. Fill in your details below and our team will get in touch with you to discuss the best franchise opportunities tailored to your needs.
Glimepiride (3mg) + Metformin (1000mg) SR Bilayered Smart Tablet
Therapeutic Category
Cardiology, Cardiovascular, Antidiabetic, Diabetic, Endocrinology
Dosage Form
Tablet
Packaging Type
Blister
Packaging
10*10
Price
₹229/-
High-resolution images and Product visuals
Product overview and usage information
Detailed information and research documents
Gimtype M3 Forte Tablet is an advanced oral antidiabetic formulation that combines Glimepiride, a sulfonylurea, and Metformin, a biguanide, in a bilayered sustained-release (SR) smart tablet. Glimepiride works by stimulating pancreatic beta cells to release insulin, thereby lowering blood glucose levels, while Metformin reduces hepatic glucose production, improves peripheral insulin sensitivity, and enhances glucose utilization by tissues. The bilayered sustained-release technology provides a controlled, prolonged release of Metformin for better glycemic stability, reduced gastrointestinal side effects, and improved patient compliance. This dual-action formulation targets both fasting and postprandial blood glucose, making it highly effective for comprehensive management of type 2 diabetes mellitus (T2DM).
Common side effects include mild hypoglycemia (due to Glimepiride), gastrointestinal disturbances such as nausea, diarrhea, abdominal discomfort (usually from Metformin), and headache. Rarely, severe hypoglycemia, lactic acidosis (especially in renal impairment), or allergic skin reactions can occur. Weight gain is possible due to sulfonylurea therapy, while Metformin may help mitigate it to some extent. Monitoring of blood glucose and renal function is essential during therapy.
Gimtype M3 Forte Tablet is indicated for the management of type 2 diabetes mellitus in adults when diet, exercise, and monotherapy with either Glimepiride or Metformin alone are insufficient to achieve optimal glycemic control. It helps in reducing the risk of diabetes-related complications such as neuropathy, nephropathy, retinopathy, and cardiovascular disease.
Gimtype M3 Forte should be taken exactly as prescribed, preferably with meals to reduce the risk of hypoglycemia and gastrointestinal side effects. It is contraindicated in type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and in conditions predisposing to lactic acidosis. Caution is advised in elderly patients and those taking other hypoglycemic agents. Alcohol intake should be minimized as it increases the risk of hypoglycemia and lactic acidosis. Regular monitoring of blood sugar, HbA1c, renal and liver function is recommended. The medication should be continued along with proper diet and exercise as part of an overall diabetes management plan.
Store Gimtype M3 Forte Tablet in a cool, dry place below 30°C, away from moisture and direct sunlight. Keep the tablets in their original packaging and out of reach of children. Do not use after the expiry date printed on the strip.
Composition : Aspirin 75mg + Rosuvastatin 10mg + Clopidogrel 75mg Tablet
Composition : Aspirin 75mg + Rosuvastatin 20mg + Clopidogrel 150mg Tablet
Composition : Aspirin 75 mg + Rosuvastatin 20 mg + Clopidogrel 75 mg capsule
Composition : Rosuvastatin 10 mg + Aspirin 75 mg tablet
Composition : Rosuvastatin 10mg + Clopidogrel 75mg Capsule
Composition : Rosuvastatin 10 mg + Ezetimibe 10 mg tablet
Composition : Rosuvastatin Calcium IP eq. to Rosuvastatin (as pellets) 20 mg. + Clopidogrel Bisulphate IP eq. to Clopidogrel 75 mg. Excipients q.s.
Composition : Rosuvastatin 5 mg tablet
Composition : Rosuvastatin 5mg + fenofibrate 160 mg tablet
Composition : Rosuvastatin 40 mg tablet
This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.
This combination has strong demand in the anti-diabetic and metabolic care segment, making it a high-value product for medical distributors, wholesalers, and pharma franchise partners focusing on diabetes management and chronic therapy portfolios.
Medical distributors and agencies can benefit from consistent demand for management of Type 2 Diabetes Mellitus, uncontrolled blood sugar levels, insulin resistance, and long-term glycemic control. Glimepiride 3mg helps stimulate insulin release from the pancreas Metformin 1000mg SR improves insulin sensitivity and reduces glucose production with sustained-release action for prolonged control The bilayered smart tablet technology supports better drug release and patient compliance This strengthens a reliable anti-diabetic and chronic-care portfolio.
Yes, Cafoli LifeCare Pvt Ltd offers PCD pharma franchise opportunities for Gimtype M3 Forte with promotional support, monopoly rights, attractive packaging, and competitive pricing for distributors and wholesalers.
Wholesalers and medical agencies benefit from high diabetic patient demand, long-term therapy usage, strong physician prescriptions, repeat monthly sales, reliable supply chain support, and good margins in anti-diabetic medicines.
Interested distributors, stockists, and wholesalers can contact Cafoli LifeCare Pvt Ltd to discuss pricing, monopoly territory rights, and distribution opportunities.